Fecal microbiota transplantation in irritable bowel syndrome: a double blind, placebo controlled trial.

Fecal microbiota transplantation in irritable bowel syndrome: a double blind, placebo controlled trial. - /

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010941

Enrollment

Registered

2016-08-24

Start date

2016-03-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrom (IBS) K58.9

Interventions

Group 1: 36 patients with IBS (18 with IBS-D and 18 with IBS-C) receive after antibiotic pretreatment 3 allogeneic FMTs via colonoscopy or sigmoidoscopy. Changes of clinical symptoms is elicited using

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with IBS, aged between 18 and 80 years, informed consent

Exclusion criteria

Exclusion criteria: -) Secondary gastrointestinal motility disorder, -) Major abdominal surgery, -) Pregnant and lactating women, -) Medication under another clinical trial, -) Serious chronic diseases such as neoplasia, autoimmune disorders or metabolic disorders.

Design outcomes

Primary

Measure	Time frame
The primary objective is to evaluate whether allogeneic FMT has a positive impact on clinical scores in IBS after 90 days.	—

Secondary

Measure	Time frame
-) Improvement of stool frequency and consistency of the Bristol-stool-scale. -) Change in intestinal microbiota -) Change the methane content of the exhaled air in the lactulose / CH4 breath test -) Subgroup analysis IBS-D and IBS-O.	—

Countries

Austria

Contacts

Public ContactPatrizia Kump

Klinische Abteilung für GastroenterologieMedizinische Universität Graz

patrizia.kump@medunigraz.at+43 316 385 80270

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026